Ffrct
Payments companies reported to CMS as associated with Ffrct. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ffrct, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ffrct
These are the largest totals companies reported as associated with Ffrct. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sarah Rinehart | Charleston, WV | Cardiovascular Disease | $283,109.12 |
| Mark Rabbat | Maywood, IL | Cardiovascular Disease | $228,820.50 |
| Michael Gallagher | Troy, MI | Cardiovascular Disease | $224,224.79 |
| Jamaluddin Moloo | Aurora, CO | Interventional Cardiology | $184,962.41 |
| Gregg Stone | New York, NY | Cardiovascular Disease | $158,451.10 |
| Ankitkumar Patel | Glen Ridge, NJ | Interventional Cardiology | $145,937.58 |
| Matthew Budoff | Torrance, CA | Cardiovascular Disease | $143,114.18 |
| Allen Taylor | N Bethesda, MD | Cardiovascular Disease | $131,879.18 |
| Michael Morris | Scottsdale, AZ | Diagnostic Radiology | $121,678.43 |
| Malissa Wood | Fort Myers, FL | Cardiovascular Disease | $111,378.50 |
Prescribed Ffrct?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.